baber/WOPTO huggingface dataset:
Patent NZ-555143-A (NZ)
Title: Compositions for HCV treatment
Inventor: LIN KAI
IPC: A61P1/16
Filed: 2005-12-20
Abstract: Provided is a pharmaceutical composition comprising a) a first agent which is a non-immunosuppressive cyclophilin-binding cyclosporin and b) one or more co-agents or pharmaceutically acceptable salts or esters thereof, wherein the co-agent is selected from the group consisting of an inhibitor of HCV NS5B polymerase and an inhibitor of CV NS34A serine protease. Further provided is use of the composition in the manufacture of a medicament for Hepatitis C or HCV induced disorders.
Patent NZ-555349-A (NZ)
Title: Improved circuitry for portable lighting devices and portable rechargeable electronic devices
Inventor: WEST STACEY
IPC: F21Y101/00
Filed: 2005-12-07
Abstract: A rechargeable electronic device is disclosed. The device includes a main power circuit including a DC power source and a power consuming load; a first charging contact electrically coupled to a first electrode of the power source via a first electrical path; a second charging contact electrically coupled to a second electrode of the power source via a second electrical path; and a short protection circuit configured to open the first electrical path at a location that is not within the main power circuit if the first charging contact and the second charging contact are shorted together.
Patent NZ-570392-A (NZ)
Title: Construction element comprising cemnet and particulate filler material
Inventor: KRUSS LEON
IPC: E04C2/04
Filed: 2007-03-20
Abstract: A construction element that includes at least 10% by weight of cement, particulate filler material comprising primarily of one ingredient or a mixture of at least two ingredients, and ethylene and vinyl acetate copolymer. The ingredient or ingredients are selected from the group consisting of particulate wood, recycled polystyrene powder, particulate expanded volcanic silicous rock (perlite), waste perlite, particulate elastomeric material, fly ash, crushed rock but not limestone, particulate paper, other cellulosic materials and sand. The components are mixed together in the presence of water, formed into a shape suitable as a construction element, and allowed to set and harden.
Patent NZ-572902-A (NZ)
Title: Encrypting and decrypting a memory card with supplementary encryption
Inventor: LIN HUI
IPC: G06F21/10
Filed: 2006-05-08
Abstract: Disclosed is a method for protecting digital contents by using memory card encryption and decryption. The method includes: formatting of a memory card with a special format; providing digital content, encrypting it, and storing it on the memory card; and then reading the contents by decrypting and de-formatting to return it to an original form to be played.
Patent NZ-574791-A (NZ)
Title: Caspase inhibitors based on pyridazinone scaffold
Inventor: CHANG HYE KYUNG
IPC: C07D237/14
Filed: 2007-07-27
Abstract: Disclosed herein is a pyridazinone compound of formula I wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as caspase inhibitors and as such are useful in the treatment or prevention of inflammation, apoptosis, dementia, cerebral stroke, brain impairment due to AIDS, diabetes, gastric ulcer, cerebral injury by hepatitis, hepatitis-induced hepatic diseases, acute hepatitis, fulminant hepatic failure, sepsis, organ transplantation rejection, rheumatic arthritis, cardiac cell apoptosis due to ischemic cardiac diseases, or liver cirrhosis.
Patent NZ-576116-A (NZ)
Title: An analytic assembly with a sample collector, an assay assembly and a quencher assembly that contains a quenching agent that inhibits interference with the optical signal produced
Inventor: GIBBONS IAN
IPC: C12M1/34
Filed: 2007-10-10
Abstract: A fluidic device 2 for detecting an analyte in a sample of bodily fluid, comprises a sample collection unit 4 adapted to provide a sample of bodily fluid into the fluidic device 2 , an assay assembly in fluidic communication with the sample collection unit 4, and a quencher assembly 9 in fluidic communication with the assay assembly. The assay assembly is adapted to yield an optical signal indicative of the presence of the analyte in the sample of bodily fluid. The quencher assembly 9 contains a quenching agent that inhibits a reaction that yields the optical signal in the quencher assembly 9, thereby reducing interference with the optical signal from the device.
Patent NZ-581335-A (NZ)
Title: A method and apparatus that facilitates continuous sequencing of packets in a wireless transmission system for transmission through a handfoff
Inventor: MEYLAN ARNAUD
IPC: H04W36/08
Filed: 2008-06-18
Abstract: An apparatus that facilitates continuous sequencing of packets for transmission through a handoff is disclosed. The apparatus comprises: (a) means for receiving one or more selectively forwarded packets for communication in connection with a handoff; (b) means for identifying state information and order information associated with the packets that facilitate lossless delivery of the packets, where at least a portion of the identifying means includes sequence number information forwarded directly from a source eNode B to a target eNode B; and (c) means for transmitting respective packets subsequent to the selectively forwarded packets using the state information in an order specified by the order information.
Patent NZ-582975-A (NZ)
Title: Transdermal delivery systems delivering sufentanil
Inventor: YUM SU II
IPC: A61K9/70
Filed: 2005-10-21
Abstract: Disclosed is a transdermal delivery system, comprising: a pressure sensitive adhesive matrix comprising sufentanil in an amount above the saturation point of sufentanil in the matrix; wherein the system provides a substantially zero order delivery rate of sufentanil over a single application administration period of at least about 48 hours and further wherein the system does not comprise a rate controlling membrane. Also disclosed is a transdermal delivery system wherein said system, when applied to said subject over a single application administration period, provides sustained analgesia in said subject for 3 or more days by delivery of sufentanil from said system with a coefficient of variation (delta J N / J N) of about 50% or less and further wherein said system does not comprise a rate controlling membrane. Further disclosed is a transdermal delivery system, wherein the system, when applied to the subject, provides delivery of sufentanil over a single application administration period of at least about 48 hours sufficient to establish and maintain a plasma sufentanil concentration having a maximum to minimum ratio of about 1.8 or less over the administration period and further wherein the system does not comprise a rate controlling membrane.
Patent NZ-585961-A (NZ)
Title: Pharmaceutically acceptable salts of methyl (3-{ [[3-(6- amino- 2-butoxy-8-oxo-7, 8-dihydro-9h-purin-9-yl) propyl] (3- morpholin-4-ylpropyl) amino] methyl } phenyl) acetate and their use in therapy
Inventor: MCINALLY THOMAS
IPC: A61K31/5377
Filed: 2008-12-16
Abstract: Disclosed is a hydrochloric acid, hydrobromic acid or maleic acid salt of methyl (3- { [[3-(6-amino-2-butoxy-8-oxo-7, 8-dihydro-9H-purin-9-yl)propyl] (3-morpholin-4-ylpropyl)amino]- methyl} phenyl)acetate or a solvate of the salt for the treatment of asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or dermatosis.
Patent NZ-591459-A (NZ)
Title: Method for inhibiting scale formation and deposition in membrane systems via the use of an aa - amps copolymer
Inventor: MUSALE DEEPAK A
IPC: C02F1/44
Filed: 2009-09-04
Abstract: Disclosed is a method of inhibiting scale formation and deposition from a feed stream passing through a membrane system which comprises the steps of a. controlling the pH of said feed stream within the range between about 7.0 and about 8.2; b. controlling the temperature of said feed stream within the range between about 5 degrees C to about 40 degrees C when the membrane system is an RO system, a NF system, an ED system, an EDI system or a combination thereof; c. controlling the temperature of said feed stream within the range between about 40 degrees C and about 80 degrees C when the membrane system is an MD system; d. measuring the turbidity of said feed stream and/or a reject stream from said membrane system; and e. adding an effective amount of a scale inhibitor to said feed stream, said scale inhibitor comprising AA-AMPS copolymer, and said scale inhibitor excluding phosphorus compounds, wherein the effective amount of the scale inhibitor is determined by measuring the turbidity of said feed stream and/or reject stream.
Patent NZ-591923-A (NZ)
Title: Inhalable particles comprising tiotropium
Inventor: AMIGHI KARIM
IPC: A61K9/00
Filed: 2009-10-02
Abstract: Disclosed is an Inhalable particles comprising a stabilised anhydrous amorphous form of tiotropium with a stabilising agent, which is a sugar derivative selected from the group consisting of a monosaccharide, a disaccharide, an oligosaccharide, a polysaccharide, and a polyalcohol. Also disclosed is where the tiotropium is tiotropium bromide and a method for preparing the inhalable particles.
Patent NZ-602296-A (NZ)
Title: Cyclopropenes and method for applying cyclopropenes to agricultural products or crops
Inventor: YOO SANG-KU
IPC: A01N27/00
Filed: 2011-04-15
Abstract: 602296 Disclosed is a method for treating plants with a 1-alkylcyclopropene represented by Formula 1 comprising: (a) mixing (i) a 1-alkylcyclopropene precursor-containing agent of Formula 2 or 3 and (ii) a fluoride-containing agent, separately supplied, to prepare 1-alkylcyclopropene of Formula 1; (b) simultaneously or continuously with step (a), phase-separating 1-alkylcyclopropene of Formula 1 from the reaction solution; and (c) applying the 1-alkylcyclopropene of Formula 1 to plants, wherein the steps are carried out in situ; wherein A represents a straight-chain linkage having the formula of (CH2)mY(CH2)n, in which m and n each independently represent an integer of 0 to 3 and Y each independently represents CH2, O or S; R1 represents substituted or unsubstituted C3-C20 alkyl or C6-C10 aryl, furanyl, pyranyl, or thienyl, each of which may be substituted with at least one selected from the group consisting of fluoride, chloride, bromide, iodide, oxygen, sulfur, nitrogen, silicon and phosphorus; R2, R3 and R4 each independently represent substituted or unsubstituted C1-C10 alkyl or alkoxy, C6-C10 aryl or aryloxy, C1-C10 primary amine or secondary amine, or halogen; and X represents halogen or OSO2T, in which T represents hydrogen, substituted or unsubstituted C1-C10 alkyl, alkoxy or aryl, aryloxy, amine, halogen or hydroxy. Representative compounds of formula (I) include (2-phenylethyl)cyclopropene, (3-phenylpropyl), (4-phenylbutyl)cyclopropene, (5-phenylpentyl)cyclopropene and Hexylcyclopropene.
Patent NZ-615719-A (NZ)
Title: Two-part electrotransport device
Inventor: LEMKE JOHN
IPC: A61N1/30
Filed: 2012-03-09
Abstract: Disclosed is a corrosion-resistant electrotransport drug delivery device. The device comprises an electrical module (20) and a reservoir module (30). The electrical module (20) and the reservoir module (30) are configured to be combined to form a unitary and activated drug delivery device prior to use. The device resists corrosion by electrically isolating a circuitry in the electrical module (20) from a power source. The electrical module comprises the circuitry (248), an electrical output and at least two power-on contacts (218) between the circuitry and a battery (290). The electrical output is adapted to connect the circuitry to an input connector on the reservoir module (30) when the electrical module (20) is combined with the reservoir module (30). The battery (290) is isolated from the circuitry (248) by the power-on contacts (218) while at least one of the power-on contacts (218) remain open and the battery (290) is connected into the circuitry (248) when all of the power-on contacts (218) are closed by battery contact actuators on the reservoir module (30) when the electrical module (20) and the reservoir module (30) are combined. The reservoir module (30) comprises an electrical input and at least two battery contact actuators (318). The electrical input adapted to electrically connect the circuitry (248) in the electrical module (20) to at least a pair of active electrodes in the reservoir module (30) when the electrical module (20) is combined with the reservoir module (30). The at least two battery contact actuators (318) are configured to close a corresponding power-on contact (218) when the electrical module (20) is combined with the reservoir module (30) so that the battery (290) is connected into the circuitry (248) and the device is powered on. The at least two battery contact actuators (318) are separated from each other.
Patent NZ-615901-A (NZ)
Title: High-pressure resistant screw connection for pipelines or hose lines having a tapered thread
Inventor: SCHIPPERS CARSTEN
IPC: F16L19/065
Filed: 2012-03-30
Abstract: A connecting device for pipelines or hose lines with a threaded body and with a pipe-like end piece which can be inserted into a receptacle formed on the threaded body and which can be fitted therein by means of a swivel nut screwed onto the threaded body. The receptacle of the threaded body has the shape of a widening cone and the circumferential surface of the end piece that engages in the receptacle has a conical design. The circumferential surface (12) of the threaded body (10) that bears the external thread (30) has, in the direction of the front end of the surface, an inclined profile directed opposite to the cone of the receptacle (11), and the swivel nut (17) has, with its surface (18) bearing the internal thread (31), a profile complementary thereto. The external thread and internal thread are designed as tapered threads in such a way that a radial force emanating from the tapered thread with the swivel nut screwed on is directed opposite to the radial force exerted, with the connecting device mounted, by the conical end piece (13) onto the receiving cone formed in the threaded body.
Patent NZ-622656-A (NZ)
Title: (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
Inventor: ORTEGA MUÑOZ ALBERTO
IPC: C07D213/74
Filed: 2012-10-22
Abstract: Disclosed herein are (hetero)aryl cyclopropylamine compounds of formula I, where the substituents are as defined herein. Also disclosed is their use in therapy, including in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Examples of the compounds of formula I include N1-((trans)-2-phenylcyclopropyl)cyclohexane-1,4-diamine and (cis)-N1-((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)cyclohexane-1,4-diamine.
Patent NZ-624493-A (NZ)
Title: Ultra-concentrated rapid-acting insulin analogue formulations
Inventor: WEISS MICHAEL
IPC: C07K14/82
Filed: 2012-10-29
Abstract: A pharmaceutical formulation comprises insulin having a variant insulin B-chain polypeptide containing an monofluoro-Phenylalanine substitution at position B24 in combination with a substitution of an amino acid containing an acidic side chain at position B10, allowing the insulin to be present at a concentration of between 0.6 mM and 3.0 mM. The formulation may optionally be devoid of zinc. Amino-acid substitutions at one or more of positions B3, B28, and B29 may additionally be present. The variant B-chain polypeptide may be a portion of a proinsulin analogue or single-chain insulin analogue. The insulin analogue may be an analogue of a mammalian insulin, such as human insulin. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to the patient.
Patent NZ-625738-A (NZ)
Title: Reduced lactose milk and methods for producing same
Inventor: Xiao yan song
IPC: A23C9/127
Filed: 2014-05-30
Abstract: Discloses a method of manufacturing a lactose-free or lactose reduced milk characterised by the steps of a) fermenting a milk including lactose with a fungi which produces the enzyme lactase and therefore is able to digest lactose, wherein the fungi is selected from the group consisting of Aspergillus Oryzae, Aspergillus sojae, Aspergillus niger, Rhizopus oryzae, Kluyveromyces lactis, Kluyveromyces fragilis and combinations thereof o digest an amount of lactose in the milk; b) substantially separating the milk from the fungi.
Patent NZ-626112-A (NZ)
Title: Triazinone compound and t-type calcium channel inhibitor
Inventor: SAITO NORIKO
IPC: C07D251/10
Filed: 2013-03-29
Abstract: Disclosed herein are triazinone compounds of formula I where the substituents are as defined herein or a tautomer or a pharmaceutically acceptable salt of the compound. The compounds have an inhibitory activity on a T-type voltage-dependent calcium channel and are useful particularly for the treatment of pain. Also disclosed are therapeutic agents and medicines comprising the compounds.
Patent NZ-628308-A (NZ)
Title: Use of succinate dehydrogenase inhibitors (sdhis) for controlling wood diseases in grape.
Inventor: MEUNIER LUCIEN
IPC: A01P3/00
Filed: 2013-02-19
Abstract: Discloses is the use of the succinate dehydrogenase SDH inhibitors (SDHIs) fluopyram, bixafen, penflufen, sedaxane, isopyrazam, penthiopyrad, furametpyr, fluxapyroxad and other SDHIs compounds for controlling wood diseases selected from the group consisting of Esca and Eutypain grape plants. Also disclosed is a method for treating wood diseases in grape by treating the seedlings, grafts and cuttings of the grape plants with the SDHIs.
Patent NZ-706363-A (NZ)
Title: Solid oral composition containing dyes for use in endoscopic diagnosis
Inventor: MORO LUIGI
IPC: A61K9/20
Filed: 2013-09-26
Abstract: Described herein is the use of a solid composition in the manufacture of a medicament for endoscopic evaluation, wherein the solid composition contains at least one dye in association with at least one physiologically acceptable excipient which comprises: a) a matrix which comprises lipophilic compounds, and optionally amphiphilic compounds, in which said at least one dye is at least partly incorporated, b) an outer matrix which comprises hydrophilic compounds in which the lipophilic matrix, and optionally the amphiphilic matrix are dispersed; c) optionally other physiologically acceptable excipients; d) optional gastro-resistant coating wherein between four and eight unit dosages thereof are to be orally administered to a human, wherein the dosage units thereof each containing about 25 mg by weight of said at least one dye are to be administered to said human prior to the endoscopic evaluation in a fractionated order at the beginning and/or during and/or at the end of a bowel cleansing preparing administration, in which a total amount from 50 to 500 mg of said at least one dye is to be administered to said human in the 48 hours prior to the endoscopic evaluation. Compositions for improved mucosal staining and ameliorating the efficacy of the diagnostic endoscopy evaluation are described.
Patent NZ-710283-A (NZ)
Title: Retractor/stabilizer for excessive and/or redundant tissue and method of use
Inventor: GALBIERZ THOMAS R
IPC: B32B7/12
Filed: 2014-01-29
Abstract: A die-cuttable retractor/stabilizer comprising a top layer having an adhesive applied one side thereof and a backing layer which covers the adhesive and which is removable from the top. The retractor/stabilizer includes a dividing cut in the backing layer which extends the width of the backing layer to separate the backing layer into an upper panel and a lower panel. A first lower panel back cut in the backing layer lower panel extends from the bottom edge of the backing layer to a point proximate the dividing cut to divide the lower panel in to at least a lower panel positioning portion and a lower panel second portion.
Patent NZ-713649-A (NZ)
Title: Method for controlling a wind park
Inventor: BEEKMANN ALFRED
IPC: F03D7/04
Filed: 2014-03-25
Abstract: The present invention relates to a method for supplying the electric power of a wind park comprising several wind turbines into an electric power supply grid. The present invention addresses the problem of managing the electric power levels if one of the several wind turbines fails to work. The solution provides a method whereby each of the wind turbines (100) provides an electric turbine output (PA) and the sum of the provided turbine outputs (PA) is supplied to the electric power supply grid (120) as wind park output (PP), and a turbine target value (PAset) is specified for each of the wind turbines (100) as a specification of the turbine output (PA) that is to be provided, and the turbine target value (PAset) is controlled via a controller (R1, R2) based on a control deviation (ΔP), as a comparison of the supplied wind park output (PPactual) and a target value (PPset) of the wind park output (PP) that is to be supplied.
Patent NZ-732934-A (NZ)
Title: Process for recycling by separating the constituents of aluminized and plasticized, optionally carton, containers, and respective equipment
Inventor: OLIVEIRA JUAREZ SOUZA DE
IPC: C08J11/06
Filed: 2015-11-18
Abstract: The patent relates to a process and equipment for recycling and reusing wastes, particularly that of plasticized, aluminized and optionally carton containers, using a method for extracting and separating the main components thereof for recycling wastes avoiding environmental pollution, recycling the waste constituents; and recovering said constituents; plastic, aluminium and paper in their original form, with the advantages of producing a polymer of reuse quality, of producing isolated aluminium, of using an easily purchased low-cost solvent, of consuming little electricity, of producing cellulose pulp that can be used for producing cardboard for manufacturing boxes, incorporated as part of a mechanical pulp filler or even continuing on to a clarification process, of having lower manufacturing and investment costs and of having a smaller cost/benefit ratio.
Patent NZ-738184-A (NZ)
Title: Methods and compositions for treating aging-associated impairments
Inventor: WYSS-CORAY ANTON
IPC: C12N15/113
Filed: 2016-05-17
Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include reducing the 2-microglobulin (B2M) level in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
Patent NZ-739518-A (NZ)
Title: Compounds useful for inhibiting ror-gamma-t
Inventor: MORPHY JOHN RICHARD
IPC: C07D495/20
Filed: 2016-09-06
Abstract: The present invention provides novel ROR gamma-t inhibitors having the structural formula shown and pharmaceutical compositions thereof.
Patent NZ-779310-A (NZ)
Title: Solid polymorphs of a flna-binding compound and its hydrochloride salts
Inventor: ZAMLOOT MICHAEL
IPC: C07D471/10
Filed: 2020-02-21
Abstract: The preparation and properties of crystalline polymorphs and solvates of 1-benzyl-8-methyl-1,4,8-triazaspiro-[4.5]-decan-2-one free base and of the mono-and dihydrochloride salts and solvates thereof are disclosed, as is an amorphous polymorph of the dihydrochloride. A pharmaceutical composition containing one or more polymorphs and a method of using that composition are also disclosed.